












WE HAVE A RICH PIPELINE OF INNOVATIVE NEW MOLECULAR ENTITIES

	PHASE 1	PHASE 2	PHASE 3/FILED	APPROVED*
 ONCOLOGY	<p>TAK-252 <i>Shattuck</i> Agonist Redirected Checkpoint Solid tumors</p> <p>TAK-573 ● <i>Teva</i> Anti-CD38-attenukine R/R MM</p> <p>TAK-079 ● Anti-CD38 mAb R/R MM, SLE</p> <p>TAK-164 <i>ImmunoGen</i> GCC-IGN ADC GI malignancies</p> <p>TAK-981 SUMO inhibitor Multiple cancers</p>	<p>TAK-228 (sapanisertib) mTORC 1/2 inhibitor Endometrial cancer</p> <p>TAK-659 ● SYK/FLT-3 inhibitor Hematologic malignancies, NHL</p> <p>TAK-788 ● EGFR/HER2 inhibitor NSCLC</p> <p>TAK-931 ● CDC7 inhibitor ESCC, sqNSCLC</p>	<p>TAK-385 (relugolix) <i>Myovant</i> GnRH antagonist Prostate Cancer (JP)</p> <p>TAK-924 ● (pevonedistat) NAE inhibitor HR-MDS/CMML</p>	<p>NINLARO ● Proteasome inhibitor</p> <p>ADCETRIS ● <i>Seattle Genetics</i> CD30 ADC</p> <p>ICLUSIG ● BCR-ABL inhibitor</p> <p>ALUNBRIG ● ALK inhibitor</p> <p>Cabozantinib <i>Exelixis</i> VEGFR/RTK inhibitor</p> <p>Niraparib <i>GlaxoSmithKline</i> PARP 1/2 inhibitor</p>
 GASTRO-ENTEROLOGY	<p>TAK-951 Peptide agonist Nausea & vomiting</p> <p>Kuma062 <i>PvP Biologics</i> Glutenase Celiac Disease</p> <p>TAK-018 <i>Enterome</i> FimH antagonist Crohn's Disease</p> <p>TAK-681 (SHP-581) GLP2r long-acting Short Bowel Syndrome</p> <p>TAK-671 <i>Samsung Bioepis</i> Protease inhibitor Acute Pancreatitis</p>	<p>TAK-906 D2/D3R antagonist Gastroparesis</p> <p>TIMP-Gliadin <i>Cour</i> Imm Tol Induction Celiac Disease</p> <p>TAK-954 <i>Theravance</i> 5-HT4R agonist POGD</p>	<p>TAK-721 ● (SHP621) <i>UCSD/Fortis</i> Oral anti-inflammatory EoE</p>	<p>ENTYVIO ● α4β7 mAb</p> <p>Vonoprazan PCAB</p> <p>ALOFISEL ● mesenchymal stem cells</p> <p>GATTEX ● GLP-2R agonist</p>
 RARE DISEASES	<p>TAK-531 ● (SHP631) <i>ArmaGen</i> I2S replacement Hunter CNS</p> <p>TAK-754 ● (SHP654) <i>Asklepios Biopharm.</i> Gene therapy Hema</p>	<p>TAK-607 (SHP607) IGF-1/IGFBP3 Chronic Lung Disease</p> <p>TAK-609 ● (SHP609) I2S replacement Hunter CNS (IT)</p> <p>TAK-611 ● (SHP611) ERT MLD</p>	<p>TAK-755 ● (SHP655) <i>KM Biologics</i> ERT/ADAMTS-13 cTTP</p> <p>TAK-620 ● (SHP620) <i>GlaxoSmithKline</i> UL97 kinase inh CMV infect. in transplant</p>	<p>OBIZUR ● <i>Ipsen</i> FVIII replacement</p> <p>VONVENDI ● vWF replacement</p> <p>NATPARA ● PTH replacement</p> <p>ADYNOVATE FVIII replacement</p> <p>TAKHZYRO ● Anti-kallikrein mAb</p>
 NEUROSCIENCE	<p>TAK-653 AMPA potentiator TRD</p> <p>TAK-418 ● LSD1 inhibitor Kabuki syndrome</p> <p>TAK-041 GPR139 agonist CIAS NS</p> <p>MEDI-1341 <i>AstraZeneca</i> Alpha-syn mAb Parkinson's Disease</p> <p>TAK-925 ● Orexin 2R agonist Narcolepsy</p> <p>WVE-120101 ● <i>Wave Life Sciences</i> mHTT SNP1 ASO Huntington's Disease</p> <p>WVE-120102 ● <i>Wave Life Sciences</i> mHTT SNP2 ASO Huntington's Disease</p>	<p>TAK-935 ● <i>Ovid Therapeutics</i> CH24H inhibitor Rare Pediatric Epilepsies</p> <p>TAK-831 DAAO inhibitor CIAS NS</p>		<p>TRINTELLIX™ <i>Lundbeck</i> Multimodal anti-depressant</p> <p>BUCCOLAM ● GABA Allosteric Modulator</p>
 PLASMA-DERIVED THERAPIES				<p>HYQVIA ● <i>Halozyme</i> IgG 10% + Recombinant Human Hyaluronidase</p> <p>CINRYZE ● PD C1 Esterase inhibitor</p>
 VACCINES	<p>TAK-021 EV71 Vaccine</p> <p>TAK-426 BARDA Zika Vaccine</p>	<p>TAK-214 Norovirus Vaccine</p>	<p>TAK-003 Dengue Vaccine</p>	<p>▶ Stage-ups since earnings announcement May 14, 2019</p> <p>▶ Stage-ups/additions since April 1, 2019</p> <p>● Orphan Drug Designation (in any region / indication for a given asset)</p> <p>● Potential for registration enabling Ph-2 study</p> <p>Assets shown in Phases 1-3 explicitly refer to new molecular entities</p>

*With ongoing significant clinical development activities; Pipeline as of July 31, 2019
Pipeline not all inclusive; programs also ongoing in other Therapeutic Areas. For glossary of disease abbreviations please refer to appendix.

MAXIMIZING THE VALUE OF OUR APPROVED PROGRAMS

	PHASE 1	PHASE 2	PHASE 3	FILED
 ONCOLOGY	ALUNBRIG® ALK inhibitor 1L ALK+NSCLC (CN)	ALUNBRIG® ALK inhibitor 2L ALK+NSCLC (JP, CN)	ICLUSIG® BCR-ABL inhibitor TKI res. chronic phase CML (US)	ADCETRIS® <i>Seattle Genetics</i> CD30 ADC R/R sALCL (CN)
		Cabozantinib <i>Exelixis</i> VEGFR/RTK inhibitor 2L HCC (JP)	NINLARO® Proteasome inhibitor R/R MM triplet Tx (GL)	ADCETRIS® <i>Seattle Genetics</i> CD30 ADC 1L PTCL (EU, JP)
		Niraparib <i>GlaxoSmithKline</i> PARP 1/2 inhibitor Ovarian cancer – maint. (JP)	NINLARO® Proteasome inhibitor Maint. ND MM no SCT (GL)	ALUNBRIG® ALK inhibitor 2L ALK+NSCLC H2H with alectinib (GL)
		Niraparib <i>GlaxoSmithKline</i> PARP 1/2 inhibitor Ovarian cancer – salvage (JP)	NINLARO® Proteasome inhibitor R/R MM doublet Tx (US, EU, JP)	Cabozantinib <i>Exelixis</i> VEGFR/RTK inhibitor 1L RCC (JP)
		ALUNBRIG® ALK inhibitor 2L ALK+NSCLC 2 nd gen TKI (GL)	NINLARO® Proteasome inhibitor Maint. ND MM post-SCT (GL)	ALUNBRIG® ALK inhibitor 1L ALK+NSCLC (EU)
 GASTRO-ENTEROLOGY			ALOFISEL® mesenchymal stem cells Perianal Fistulas in CD (US, JP)	ENTYVIO® α4β7 mAb SubQ UC (US)
			GATTEX GLP-2R agonist Adult-SBS (JP)	ENTYVIO® α4β7 mAb SubQ UC (US, JP)
			GATTEX GLP-2R agonist Pediatric-SBS (JP)	ENTYVIO® α4β7 mAb SubQ UC (EU)
				ENTYVIO® α4β7 mAb SubQ UC (EU)
				Vonoprazan PCAB Acid-related diseases (CN)
				ENTYVIO® α4β7 mAb Ulcerative Colitis (CN)
				ENTYVIO® α4β7 mAb Crohn's Disease (CN)
 RARE DISEASES	NATPARA PTH replacement Hypothyroidism (JP)		OBIZUR <i>Ipsen</i> FVIII replacement CHAWI (US, EU)	TAKHZYRO Anti-kallikrein mAb HAE prophylaxis (CN)
			ADYNOVATE Pediatric Hema (EU)	
 NEUROSCIENCE			BUCCOLAM GABA Allosteric Modulator Status Epilepticus (JP)	TRINTELLIX™ <i>Lundbeck</i> Multimodal anti-depressant MDD (JP)
 PLASMA-DERIVED THERAPIES			CINRYZE PD C1 Esterase inhibitor HAE prophylaxis (JP)	
			HYQVIA <i>Halozyme</i> IgG 10% + Recombinant Human Hyaluronidase CIDP	
			HYQVIA <i>Halozyme</i> IgG 10% + Recombinant Human Hyaluronidase Pediatric PID (US)	

- ▶ Stage-ups since earnings announcement May 14, 2019
- ▶ Stage-ups/additions since April 1, 2019
- Orphan Drug Designation (in any region / indication for a given asset)
- Potential for registration enabling Ph-2 study
- Assets shown in Phases 1-3 explicitly refer to new molecular entities

Pipeline as of July 31, 2019; region abbreviations: GL = global (USA, Europe, Japan, China). Pipeline not all inclusive; programs also ongoing in other Therapeutic Areas
 For glossary of disease abbreviations please refer to appendix